SQI Diagnostics Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew Morris
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 36 Meteor Drive Toronto ON Canada M9W 1A4
- IPO Date
- Aug 11, 2009
- Website
- sqidiagnostics.com
- Similar Companies
- Business
- SQI Diagnostics Inc. (TSX-V: SQD; OTCQB: SQIDF) develops and commercializes precision medicine diagnostic tests focused on lung health, organ transplant monitoring, autoimmune diseases, and infectious conditions including COVID-19; its core offerings feature the proprietary microarray-based diagnostic platform with automated systems for biomarker testing, RALI-dx COVID-19 Severity Triage Test, RALI-fast IL-6 Severity Triage Point-of-Care Test, TORdx LUNG Test for ex-vivo lung perfusion biomarker analysis, direct-to-consumer COVID-19 HOME Antibody Test, Celiac Disease and Rheumatoid Arthritis screening tests, and immunological protein/antibody assays. Founded in 2003 and headquartered at 36 Meteor Drive in Toronto, Ontario, Canada, the company targets healthcare providers, patients, and consumers primarily in North America through laboratory-based, point-of-care, and direct-to-consumer formats; it operates in the biotechnology research and medical diagnostics industry with a pipeline of over 20 products addressing immune, respiratory, infectious, and other diseases. Recent developments include advancing four new diagnostic products in partnership with University Health Network and exploring Owlstone Medical's breath biopsy for fungal infection detection in lung transplant patients as of 2023, alongside a 2022 acquisition of Precision Biomonitoring's SARS-CoV-2 testing business and related PCR technologies for $6.8 million to expand molecular diagnostics capabilities, a new capital markets consulting agreement in 2023, and ongoing strategic review for potential sale or merger.
SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options
SQI Diagnostics Inc. Announces Grant of Stock Options
SQI Diagnostics Reports Third Quarter 2021 Results
FDA Stops Emergency Use Authorization Review of SQI Diagnostics RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients
SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's COVID-19 HOME Antibody Test
SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders
SQI Diagnostics Inc. Announces Grant of Stock Options
SQI Diagnostics Reports Second Quarter 2021 Results and Announces Departure of CEO and Appointment of Interim CEO
SQI Diagnostics Submits RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
SQI Diagnostics Reports First Quarter 2021 Results
SQI Diagnostics Reports Fourth Quarter and Fiscal 2020 Results